Johnson & Johnson

JNJ

Market cap $556B

Earned income has a ceiling. Passive income from dividend stocks operates differently: cash flows in whether markets are up or down, whether you're working or sleeping.

Johnson & Johnson's JNJ first-quarter results were better than expected as it beat estimates for both earnings and sales. Despite the blockbuster drug, Stelara's loss of exclusivity (LOE), the Innovative Medicines unit once again outperformed expectations as sales of most key drugs like Darzalex, Tremfya and Erleada beat estimates.

Johnson & Johnson exceeded expectations in its Q1 2026 earnings report. Investors weren't blown away by the results.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

A U.S. judge has ‌rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that its multibillion-dollar drug cuts the risk of death from prostate cancer in half.

A federal judge rejected ​Bayer's request for ‌an injunction to block Johnson & Johnson's alleged ​false advertising that ​its multibillion-dollar drug cuts ⁠the risk of ​death from prostate cancer ​in half.

Johnson & Johnson only slightly raised its 2026 financial guidance. So JNJ expects its operational sales to be between $99.7 billion and $100.7 billion, up from $99.5 billion to $100.5 billion. In my view, this is due to the sharp decline in demand for Stelara, JNJ's former "cash cow" in the immunology franchise.

SKT and peers boost dividends as inflation rates and geopolitical risks drive demand for steady income plays in a volatile market.

J&J's stock has rallied over the past 12 months. It's a solid safe-haven stock, but it could have more upside than its peers.

This trio has typically outpaced the S&P 500 in economic downturns. The three are healthcare leaders with plenty of size and diversity.